13G Filing: Baker Bros. Advisors and Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
...... (read more)
Bellicum Pharmaceuticals Inc (BLCM)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Frazier Healthcare Partners Alan Frazier | 1,051,441 | $3,543 | 0.85% | |
| 2. | Dorset Management David M. Knott | 126,127 | $425 | +14% | 0.16% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,677,818 | $9,024 | 0.05% | |
| 4. | DAFNA Capital Management Nathan Fischel | 30,000 | $101 | 0.04% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 53 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.56 | 10,000 | Director | 10,000 | 2018-11-09 | Filing | |
| $12.00 | 151,177 | Large Shareholder | 4,527,089 | 2017-03-24 | Filing | |
| $12.00 | 15,489 | Large Shareholder | 434,760 | 2017-03-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.04 | 10,000 | Officer | 89,939 | 2018-09-04 | Filing | |
| $7.63 | 40,000 | Officer | 99,939 | 2018-07-18 | Filing | |
| $7.97 | 6,206 | Officer | 26,548 | 2018-05-25 | Filing | |
| $7.91 | 4,136 | Large Shareholder | 58,131 | 2018-01-19 | Filing | |
| $7.91 | 265,708 | Large Shareholder | 3,734,776 | 2018-01-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 109,832 | $370 | 0.25% | |
| 2. | 1,379,629 | $4,649 | 0.13% | |
| 3. | 1,060,838 | $3,575 | 0.09% | |
| 4. | 129,417 | $436 | 0.04% | |
| 5. | 30,400 | $102 | 0.04% |
News See All
13D Filing: Baker Bros. Advisors Owns 18% of Bellicum Pharmaceuticals, Inc (BLCM)
At Insider Monkey, we closely monitor the moves made by activist investors. Their targets are often undervalued stocks with firm foundations that for one reason or another have failed to execute. At times...... (read more)
A Look At Three Activist Moves By Several Elite Hedge Funds
According to the Schulte, Roth & Zabel’s Activist Investing 2015 Annual Review, 344 companies were targeted by activist investors in 2014, as compared with 291 recorded a year earlier. Shareholder...... (read more)
Hedge Fund Sentiment Is Stagnant On Bellicum Pharmaceuticals Inc (BLCM)
A market correction in the third quarter, spurred by a number of global macroeconomic concerns ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller...... (read more)
Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Group’s Top New Picks
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February. The hedge fund is particularly...... (read more)
Bellicum Pharmaceuticals Inc (BLCM): Baker Bros. Discloses 16% Passive Stake
As a new filing with the Securities and Exchange Commission showed, Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has been added to the equity portfolio of Julian and Felix Bakers' healthcare-focused hedge...... (read more)
Billionaire Hedge Funds
